NO20054976L - Anvendelse av erytropoietin ved rekonvalens eller slag - Google Patents

Anvendelse av erytropoietin ved rekonvalens eller slag

Info

Publication number
NO20054976L
NO20054976L NO20054976A NO20054976A NO20054976L NO 20054976 L NO20054976 L NO 20054976L NO 20054976 A NO20054976 A NO 20054976A NO 20054976 A NO20054976 A NO 20054976A NO 20054976 L NO20054976 L NO 20054976L
Authority
NO
Norway
Prior art keywords
erythropoietin
reconstitution
stroke
epo
invention demonstrates
Prior art date
Application number
NO20054976A
Other languages
English (en)
Norwegian (no)
Inventor
Kenneth Rhodes
Michael Gold
Michael J Renzi
Navneeth Thirumalai
Francis Farrell
Linda Jolliffe
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20054976L publication Critical patent/NO20054976L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
NO20054976A 2003-03-27 2005-10-26 Anvendelse av erytropoietin ved rekonvalens eller slag NO20054976L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45819303P 2003-03-27 2003-03-27
US47749403P 2003-06-11 2003-06-11
PCT/US2004/009443 WO2004087063A2 (en) 2003-03-27 2004-03-26 Use of erythropoietin in stroke recovery

Publications (1)

Publication Number Publication Date
NO20054976L true NO20054976L (no) 2005-10-26

Family

ID=33135092

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054976A NO20054976L (no) 2003-03-27 2005-10-26 Anvendelse av erytropoietin ved rekonvalens eller slag

Country Status (11)

Country Link
US (1) US20040209812A1 (ja)
EP (1) EP1633383A4 (ja)
JP (1) JP2006521405A (ja)
AU (1) AU2004226372A1 (ja)
BR (1) BRPI0408829A (ja)
CA (1) CA2519803A1 (ja)
MX (1) MXPA05010345A (ja)
NO (1) NO20054976L (ja)
NZ (1) NZ542092A (ja)
RU (1) RU2341284C2 (ja)
WO (1) WO2004087063A2 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
WO2003018782A2 (en) * 2001-08-30 2003-03-06 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
WO2003024472A2 (en) 2001-09-14 2003-03-27 Stem Cell Therapeutics Inc. Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
AU2002325710A1 (en) * 2001-09-18 2003-04-01 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
AU2003250705A1 (en) * 2002-07-31 2004-02-16 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
MXPA05012515A (es) * 2003-05-19 2006-05-25 Kenneth S Warren Inst Inc Citocinas protectoras de tejido para la proteccion, restablecimiento y potenciacion de celulas, tejidos y organos sensibles, con una ventana terapeutica ampliada.
BRPI0414887A (pt) * 2003-09-29 2006-12-12 Warren Pharmaceuticals Inc E T métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica
JP4990634B2 (ja) 2004-02-13 2012-08-01 ステム セル セラピューティクス コーポレイション 神経幹細胞の増殖および神経発生のための黄体化ホルモン（ＬＨ）、および絨毛性ゴナドトロピン（ｈＣＧ）の使用
BRPI0412869A (pt) * 2004-05-20 2006-10-03 Kenneth S Warren Inst Inc uso de uma eritropoietina ou uma citocina protetora de tecido, e, método para proteger ou manter a viabilidade de uma célula, tecido ou órgão mamìferos responsivos
CA2664629A1 (en) 2005-09-27 2007-04-05 Christopher Gregg Oligodendrocyte precursor cell proliferation regulated by prolactin
CA2643502A1 (en) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Dosing regimes for lh or hcg and epo for treatment of neurological disorders
JP5326079B2 (ja) * 2006-06-07 2013-10-30 国立大学法人徳島大学 エリスロポエチンを用いた虚血性疾患の治療
CA2744289A1 (en) * 2008-11-25 2010-06-03 Otsuka Pharmaceutical Co., Ltd. Stem cell for therapeutic use which is derived from human monocyte, and method for inducing same
RU2495688C1 (ru) * 2012-03-28 2013-10-20 Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" Способ лечения ишемии головного мозга в эксперименте
RU2496513C1 (ru) * 2012-09-27 2013-10-27 Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" Способ лечения ишемии спинного мозга в эксперименте

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
CN1607957B (zh) * 1999-04-13 2012-10-10 肯尼思S.沃伦协会有限公司 外周给药的红细胞生成素对应激组织功能的调制
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
MXPA05012515A (es) * 2003-05-19 2006-05-25 Kenneth S Warren Inst Inc Citocinas protectoras de tejido para la proteccion, restablecimiento y potenciacion de celulas, tejidos y organos sensibles, con una ventana terapeutica ampliada.

Also Published As

Publication number Publication date
WO2004087063A3 (en) 2005-05-19
RU2005130023A (ru) 2006-03-20
EP1633383A4 (en) 2008-05-21
WO2004087063A2 (en) 2004-10-14
EP1633383A2 (en) 2006-03-15
BRPI0408829A (pt) 2006-04-04
NZ542092A (en) 2008-04-30
JP2006521405A (ja) 2006-09-21
AU2004226372A1 (en) 2004-10-14
RU2341284C2 (ru) 2008-12-20
US20040209812A1 (en) 2004-10-21
CA2519803A1 (en) 2004-10-14
MXPA05010345A (es) 2006-03-08

Similar Documents

Publication Publication Date Title
NO20054976L (no) Anvendelse av erytropoietin ved rekonvalens eller slag
ECSP088430A (es) Diarilurea para el tratamiento de hipertensión pulmonar
BRPI0410630A (pt) antagonista de nk1
CY1108714T1 (el) Ανταγωνιστες υποδοχεα cgrp
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
DE602004023725D1 (de) Muteine von tränen-lipocalin
ATE385419T1 (de) Dermatologische und kosmetische zusammensetzungen enthaltend ein furfurylderivat
DE60314495D1 (de) Aminosäuresequenzen die die fähigkeit besitzen, die durchdringung durch eine biologische barriere erleichtern
ATE498608T1 (de) Sulfone, die die aktivität von gamma-secretase modulieren
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
ATE368031T1 (de) Neue gamma secretase inhibitoren
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
ATE485269T1 (de) C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
ATE368656T1 (de) Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
ATE484505T1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
NO20060718L (no) Substituerte tiofoner og deres anvendelse
ATE356606T1 (de) Juckreizstillende kosmetische und dermatologische zubereitungen
ATE398996T1 (de) Haarkonditionierungszusammensetzung
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
NO20065835L (no) Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander
NO20001781L (no) 3-amino-3-arylpropan-1-og lignende-derivater, deres fremstilling og anvendelse
DE602005007471D1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren
BR0100678A (pt) Composições em forma de gel e agentes de tratamento de cabelo espessados

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application